FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Eansor Norman David 2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [ TECH ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President-Protein Sciences
(Last)         (First)         (Middle)
8100 SOUTHPARK WAY, A-8
3. Date of Earliest Transaction (MM/DD/YYYY)
5/28/2020
(Street)
LITTLETON, CO 80120
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  5/28/2020    M    3448  A $108.49  3448  D 
 
Common Stock  5/28/2020    S    3448  D $260.1897 (1) 0  D 
 
Common Stock  5/29/2020    M    7909  A $108.49  7909  D 
 
Common Stock  5/29/2020    S    1700  D $260.8292 (2) 6209  D 
 
Common Stock  5/29/2020    S    3400  D $261.7431 (3) 2809  D 
 
Common Stock  5/29/2020    S    2100  D $262.6759 (4) 709  D 
 
Common Stock  5/29/2020    S    709  D $264.0119 (5) 0  D 
 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy)  $108.49  5/28/2020    M        3448    (7) 8/7/2022  Common Stock  3448  $0  7909  D 
 
Stock Options (Right to Buy)  $108.49  5/29/2020    M        7909    (7) 8/7/2022  Common Stock  7909  $0  0  D 
 
Stock Options (Right to Buy)  $106.59                   (7) 8/18/2023  Common Stock  14114    14114  D 
 
Stock Options (Right to Buy)  $106.59                   (8) 8/18/2023  Common Stock  18819    18819  D 
 
Restricted Stock Units   (6)                  (9)  (9) Common Stock  2174    2174  D 
 
Stock Options (Right to Buy)  $125.05                   (9) 8/9/2024  Common Stock  11982    11982  D 
 
Stock Options (Right to Buy)  $125.05                   (10) 8/9/2024  Common Stock  15976    15976  D 
 
Restricted Stock Units   (6)                  (11)  (11) Common Stock  2537    2537  D 
 
Stock Options (Right to Buy)  $177.32                   (11) 8/8/2025  Common Stock  13550    13550  D 
 
Stock Options (Right to Buy)  $177.32                   (12) 8/8/2025  Common Stock  18066    18066  D 
 
Restricted Stock Units   (6)                  (13)  (13) Common Stock  3151    3151  D 
 
Stock Options (Right to Buy)  $190.41                   (13) 8/7/2026  Common Stock  15948    15948  D 
 
Stock Options (Right to Buy)  $190.41                   (14) 8/7/2026  Common Stock  21265    21265  D 
 

Explanation of Responses:
(1)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.0000 to $260.6600, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(2)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.2500 to $261.2100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(3)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.2500 to $262.2400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(4)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.3150 to $263.2300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(5)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.6168 to $264.5700, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(6)  Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
(7)  Fully exercisable.
(8)  Options to purchase 4,705 shares vest on each of 8/18/2017, 8/18/2018 and 8/18/2019 and options to purchase 4,704 shares vest on 8/18/2020.
(9)  Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(10)  Options to purchase 3,994 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.
(11)  Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(12)  Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
(13)  Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(14)  Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Eansor Norman David
8100 SOUTHPARK WAY, A-8
LITTLETON, CO 80120


President-Protein Sciences

Signatures
/s/ Brenda S. Furlow as Attorney-in-Fact for N. David Eansor pursuant to Power of Attorney previously filed. 6/1/2020
**Signature of Reporting Person Date
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Bio Techne Charts.
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Bio Techne Charts.